With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.23462-75-1,Dihydro-2H-pyran-3(4H)-one,as a common compound, the synthetic route is as follows.
To a stirred solution of the dihydro-2H-pyran-3(4H)-one (commercially available from Pharm lab Product list, 21.6 g, 0.216 mol) in 160 ml of dry THF , trimethyl silyl chloride(58.7g, 68.5 ml, 0.54 mol) was added under argon at room temperature, then the mixture was allowed to stir 10 minutes .At this mixture triethylamine (59.7g, 82.2 ml, 0.59 mol) was added dropwise and under vigorous stirring (strong precipitation). The resulting suspension was heated to reflux for 48 hours, then the mix was cooled to r.t and concentrated to 1/3 of the volume at the rotavapor (T=40C, p=200 mbar). At this crude 300 ml of pentane were added to allow the complete precipitation of TEA.HCI and the suspension was filtered.The solid was washed with 100 ml of pentane and the resulting filtrate was separated.The desired product was isolated by fract. Distillation; pentane and THF residue were removed at athmospheric pressure and the sililenolether was isolated at Tdist=58-60C p=5mbar. Obtained 28.7 g of the title compound as colourless oilMS (ES) (mlz): 172 [M+H]+1H NMR (CDCI3 ) :delta 0.20 (s,9H), 1.92-2.32 (m, 2H), 3.67 (t, J=5.5 Hz, 2H), 3.78-3.95 (m,2H), 4.78-5.05 (m,1 H), 23462-75-1
23462-75-1 Dihydro-2H-pyran-3(4H)-one 90109, aTetrahydropyrans compound, is more and more widely used in various fields.
Reference£º
Patent; Glaxo Group Limited; WO2009/43883; (2009); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics